Dustin Higgins, DO
Endocrinology, Diabetes & Metabolism · Quincy, ILNPI 1306157409
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 65.6% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $15,433 and has fallen 92.6% since, to $1,141 in 2025.
Across 626 payments — averaging $38.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$16K
- Amgen$2K
- Abbott$1K
- AstraZeneca$1K
- Lilly USA, LLC$768
- Corcept Therapeutics$657
- plus $3K from 20 others
What the payments were for
- Speaking & faculty fees$12,36652%
- Travel & lodging$2,70211%
- Food & beverage$8,85037%
- Education$610%
- Other$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 157 | $15,745 |
| Amgen(2 entities) | 17 | $1,568 |
| Abbott | 116 | $1,161 |
| AstraZeneca(2 entities) | 58 | $1,031 |
| Lilly USA, LLC | 50 | $768 |
| Corcept Therapeutics | 39 | $657 |
| Sanofi-aventis U.S. LLC | 33 | $487 |
| Insulet Corporation | 21 | $340 |
| Xeris Pharmaceuticals, Inc. | 17 | $335 |
| Boehringer Ingelheim | 22 | $325 |
| Bayer | 17 | $274 |
| Tandem Diabetes Care, Inc. | 10 | $201 |
| Johnson & Johnson | 13 | $176 |
| Radius Health, Inc. | 9 | $175 |
| Medtronic | 11 | $153 |
| Dexcom, Inc. | 6 | $109 |
| Sequel Med Tech, LLC | 6 | $106 |
| Merck | 7 | $105 |
| AbbVie | 4 | $65 |
| Recordati_rare_diseases_inc. | 3 | $62 |
| Amarin Pharma, Inc. | 4 | $60 |
| Welch Allyn | 2 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Optos, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,002 in reported general payments places this provider in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 216 | $295,129 |
| TrulicityDulaglutide | 177 | $216,409 |
| MounjaroTirzepatide | 145 | $171,361 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 114 | $109,703 |
| JardianceEmpagliflozin | 105 | $85,961 |
| FarxigaDapagliflozin Propanediol | 81 | $77,059 |
| Tresiba Flextouch U-200Insulin Degludec | 74 | $75,297 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $61,549 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 41 | $54,169 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 42 | $49,372 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 72 | $33,840 |
| Novolog FlexpenInsulin Aspart | 177 | $31,723 |
| Humalog Kwikpen U-100Insulin Lispro | 117 | $29,561 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $27,220 |
| JanuviaSitagliptin Phosphate | 22 | $27,063 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $768 | $393,033373 claims |
| Novo NordiskOzempic, Novolog, Fiasp | $15,745 | $316,408290 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $487 | $113,565130 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $325 | $105,664130 claims |
| AstraZenecaFarxiga | $1,031 | $77,05981 claims |
| MerckJanuvia | $105 | $27,06322 claims |
| Johnson & JohnsonInvokana | $176 | $13,40916 claims |
| AbbVieSynthroid, Armour Thyroid | $65 | $7,51989 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Quincy
- Sandra DempseyQuincy$10K
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Babak PazookiJoliet$582K
- Ammar BayrakdarEvergreen Park$517K
- George BakrisChicago$403K
- Terrence SwadeLombard$369K
- Wenyu HuangChicago$341K
- Liana BillingsSkokie$295K
- Daniel SoArlington Heights$283K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.